Patient mobility is a key issue in the EU who recently passed a new law on patients right to EU-wide provider choice. In this paper we use a Hotelling model with two regions that differ in technology to study the impact ...

We analyse how a patent-holding pharmaceutical firm may strategically use advertising of existing drugs to affect R&D investments in new (differentiated) drugs, and thereby affect the probability distribution of future ...

We study the price level of pharmaceuticals in Sweden relative to the following nine European countries; Austria, Belgium, Denmark, Finland, Germany, Ireland, the Netherlands, Norway, and United Kingdom (UK). Our sample ...

In a model of spatial competition, we analyse the equilibrium outcomes in markets where the product price is exogenous. Using an extended version of the Hotelling model, we assume that firms choose their locations and the ...

We study the relationship between regulatory regimes and pharmaceutical firms pricing strategies using a unique policy experiment from Norway, which in 2003 introduced a reference price (RP) system called “index pricing” ...

We study the impact of regulatory regimes on generic competition and pharmaceutical pricing using a unique policy experiment in Norway, where reference pricing (RP) replaced price cap regulation in 2003 for a sub-sample ...